Study title/design: A study to evaluate the efficacy and safety of oral zavegepant in migraine prevention (NCT04804033) Trial NCT04804033. Estimated completion December 15 2027 Aim To compare the efficacy of zavegepant (BHV-3500) to placebo as a preventive treatment for migraine, as measured by reduction in number of migraine days per month (MMD). Study design Phase …
Read more »Study title/design: Long term safety study of zavegepant (BHV-3500) for the acute treatment of migraine (NCT04408794) Trial NCT04408794. Completed December 23 2021 Aim To evaluate the safety and efficacy of three different intranasal dose levels of zavegepant (BHV-3500), relative to placebo, in the acute treatment of moderate to severe migraine. Study design Phase 2/3, open-label, …
Read more »Study title/design: Acute treatment trial of zavegepant (BHV-3500) in adults with migraine (NCT03872453) Trial NCT03872453. Completed November 11 2019 Aim To evaluate the safety and efficacy of three different intranasal dose levels of zavegepant (BHV-3500), relative to placebo, in the acute treatment of moderate to severe migraine. Study design Phase 2/3, double-blind, randomised, placebo-controlled, dose-ranging …
Read more »Study title/design: Randomised trial of zavegepant (BHV-3500) in adults with acute migraine (NCT04571060) Trial NCT04571060. Completed October 22 2021 Aim To test the safety and efficacy of zavegepant (BHV-3500) versus placebo, in the acute treatment of moderate to severe migraine. Study design Phase 3, double-blind, randomised, placebo-controlled, safety and efficacy trial of intranasal zavegepant 10 …
Read more »
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
